Protagonist Therapeutics notches a milestone in its pact with Takeda for rusfertide. New data show that many patients with a ...

BTIG raised the firm’s price target on Protagonist Therapeutics (PTGX) to $73 from $67 and keeps a Buy rating on the shares. Positive VERIFY ...

Takeda paid Protagonist $300 million one year ago to license rights to rusfertide, which the companies are developing to ...

Protagonist Therapeutics (NASDAQ:PTGX) and Takeda (NYSE:TAK) said on Monday that its late-stage study of rusfertide for the ...

Among phlebotomy-dependent patients with polycythemia vera, the addition of rusfertide to standard-of-care treatment resulted ...

Majima is an interesting case as he's the only character on this list who didn't debut as a protagonist; instead it took six entire games for him to become playable. Luckily for him though ...

"Protagonist is quickly approaching multiple late-stage transformational events expected in the first quarter of this year, including the topline results from the VERIFY Phase 3 study of rusfertide in ...